IPO value of select CAR-T companies 2013-2015

This statistic shows IPO values of selected companies with a CAR-T (chimeric antigen receptor T-cell) focus between 2013 and 2015. Kite Pharma had an IPO value of 128 million U.S. dollars in June 2014.

Selected IPOs of companies with a CAR-T focus between 2013 and 2015 (in million U.S. dollars)*

IPO value in million U.S. dollars
Bluebird bio (June 2013)101
Kite (June 2014)128
Bellicum (December 2014)140
Juno (December 2014)265
Cellectis (March 2015)228
Ceylad (May 2015)100
Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

December 2017

Region

United States

Survey time period

as of 2017

Supplementary notes

* CAR-T = chimeric antigen receptor T-cell.
Only includes IPOs where the company had a CAR-T focus at the time of going public. Source: Company press releases.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Cell and gene therapy"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.